{
  "abstract": "Background and Importance Talquetamab is a humanised bispecific antibody targeting CD3 on T-cells and GPRC5D on myeloma cells, used in relapsed or refractory multiple myeloma (RRMM). While pivotal trials have shown promising results, real-world evidence remains essential to confirm effectiveness and safety in routine practice.Aim and Objectives To evaluate the effectiveness and safety of talquetamab in RRMM patients treated in two general university hospitals.Material and Methods Observational, descriptive, retrospective, multicentre study conducted between January 2023-September 2025. Patients received, at least, three prior treatment lines: an immunomodulatory agent, a proteasome inhibitor, an anti-CD38 antibody. Variables included sex, age, myeloma type, number of prior therapies, effectiveness (monoclonal component (MC), total proteins (TP), progression-free survival (PFS)) and safety (adverse events (AE)). Effectiveness was defined as achieving normal TP values (6-8.3mg/dl) and undetectable MC.Results Six patients (mean age 77.6±5 years) were included: three men (patients 1, 2, 6), three women (patients 3, 4, 5). Another patient was excluded due to use of talquetamab as bridging therapy before CAR-T. Patients 1, 2, 5 had MM IgG-lambda; patient 3 MM IgG-kappa; patient 4 MM IgA; patient 6 biclonal gammapathy IgG-kappa/lambda. Patients 2, 3, 6 were refractory to three prior lines; patients 4, 5 to five; patient 1 to four.All received step-up dosing (0.01-0.8 mg/kg), except patient 5 due to cytomegalovirus reactivation. All achieved normal TP. Only patient 3 reached undetectable MC, remaining in complete remission after 28 cycles. Initially on biweekly 0.8mg/kg, from May 2025 her regimen was adjusted to every 21 days. The remaining patients discontinued due to progression (mean PFS 3.6±2 months).All patients required immunoglobulin supplementation due to infection risk. Patients 2, 3, 4 developed grade I cytokine release syndrome (CRS). Patient 4 also developed grade-II immune effector cell-associated neurotoxicity syndrome (ICANS), treated with dexamethasone and tocilizumab. Patients 1, 5, developed grade-II CRS. Patient 5 received rasburicasa due to tumour lysis syndrome. Additional AEs: asthenia (100%), skin lesions and infections (57.1% each), hepatic, haematologic, digestive alterations (28.6% each), cardiac dysfunction and facial paralysis (14.3% each).Conclusion and Relevance Only one patient achieved complete remission and continues treatment. The most common AEs were asthenia, skin lesions and infections. CRS and ICANS were successfully managed with supportive therapy. Larger real-world studies are needed to confirm these findings about safety and effectiveness of talquetamab.Conflict of Interest No conflict of interest",
  "authors": [
    {
      "affiliations": [
        "Infanta Sofia University Hospital, Pharmacy Department, Madrid, Spain"
      ],
      "name": "L Coiduras Del Olmo"
    },
    {
      "affiliations": [
        "Jiménez Díaz Foundation University Hospital, Pharmacy Department, Madrid, Spain"
      ],
      "name": "P Ortega Menéndez"
    },
    {
      "affiliations": [
        "Infanta Sofia University Hospital, Pharmacy Department, Madrid, Spain"
      ],
      "name": "G Pinilla Lebrero"
    },
    {
      "affiliations": [
        "Infanta Sofia University Hospital, Pharmacy Department, Madrid, Spain"
      ],
      "name": "E García Martín"
    },
    {
      "affiliations": [
        "Infanta Sofia University Hospital, Pharmacy Department, Madrid, Spain"
      ],
      "name": "Á Narrillos Moraza"
    },
    {
      "affiliations": [
        "Infanta Sofia University Hospital, Pharmacy Department, Madrid, Spain"
      ],
      "name": "M Loysele Susmozas"
    },
    {
      "affiliations": [
        "Infanta Sofia University Hospital, Pharmacy Department, Madrid, Spain"
      ],
      "name": "E Martín Vega"
    },
    {
      "affiliations": [
        "Infanta Sofia University Hospital, Pharmacy Department, Madrid, Spain"
      ],
      "name": "E López Aspiroz"
    },
    {
      "affiliations": [
        "Infanta Sofia University Hospital, Pharmacy Department, Madrid, Spain"
      ],
      "name": "A Martínez Hernández"
    }
  ],
  "title": "4CPS-069 Real-life experience with talquetamab in relapsed or refractory multiple myeloma: case report",
  "uid": "29bcf9ed-3fa7-51f2-a04e-abbb267cd624"
}